Cargando…

Pooled analysis of the clinical benefit of cyclooxygenase-2 inhibitors combined with chemotherapy in advanced non-small cell lung cancer

BACKGROUND: The purpose of this study was to perform a systematic review of the interventions for advanced non-small cell lung cancer (NSCLC) including chemotherapy alone and chemotherapy plus COX-2 inhibitors to identify and discuss the cause of any variation across studies and to explore the best...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zheng, Wei, Liao, Zhi-Min, Fu, Yan, Wu, Ya-Peng, Zhang, Qiong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2019
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8798089/ https://www.ncbi.nlm.nih.gov/pubmed/35116868 http://dx.doi.org/10.21037/tcr.2019.07.06

Ejemplares similares

Clinical benefit of COX-2 inhibitors in the adjuvant chemotherapy of advanced non-small cell lung cancer: A systematic review and meta-analysis
por: Xu, Yu-Qiong, et al.
Publicado: (2021)

Combined Effects of Cyclooxygenase-1 and Cyclooxygenase-2 Selective Inhibitors on Ovarian Carcinoma in Vivo
por: Li, Wei, et al.
Publicado: (2011)

Effect of cyclooxygenase inhibitor use on immunotherapy efficacy in non‐small cell lung cancer
por: Kanai, Osamu, et al.
Publicado: (2021)

Efficacy and safety of combined immunotherapy and antiangiogenesis with or without chemotherapy for advanced non-small-cell lung cancer: A systematic review and pooled analysis from 23 prospective studies
por: Gao, Ruo-Lin, et al.
Publicado: (2022)

Intrathecal chemotherapy as a treatment for leptomeningeal metastasis of non-small cell lung cancer: A pooled analysis
por: Wu, Ya-Lan, et al.
Publicado: (2016)

Comparison of a combination of chemotherapy and immune checkpoint inhibitors and immune checkpoint inhibitors alone for the treatment of advanced and metastatic non‐small cell lung cancer
por: Kuo, Chih‐Hsi Scott, et al.
Publicado: (2019)

PD-1 inhibitor plus chemotherapy versus bevacizumab plus chemotherapy in patients with advanced non-squamous non-small-cell lung cancer: a pooled analysis of three randomised trials
por: Meng, Xiangjiao, et al.
Publicado: (2022)

Cannabinoid system and cyclooxygenases inhibitors
por: Păunescu, H, et al.
Publicado: (2011)

Antitumor enhancement of celecoxib, a selective Cyclooxygenase-2 inhibitor, in a Lewis lung carcinoma expressing Cyclooxygenase-2
por: Park, Won, et al.
Publicado: (2008)

Radiofrequency deep hyperthermia combined with chemotherapy in the treatment of advanced non-small cell lung cancer
por: Yang, Wen-Hui, et al.
Publicado: (2019)

Intracranial activity of first-line immune checkpoint inhibitors combined with chemotherapy in advanced non-small cell lung cancer
por: Huang, Zhe, et al.
Publicado: (2023)

Cyclooxygenase-2 Inhibitor: A Potential Combination Strategy With Immunotherapy in Cancer
por: Pu, Dan, et al.
Publicado: (2021)

Clinical Profile of Cyclooxygenase-2 Inhibitors in Treating Non-Small Cell Lung Cancer: A Meta-Analysis of Nine Randomized Clinical Trials
por: Zhou, Yuan Yuan, et al.
Publicado: (2016)

Cyclooxygenase-2 inhibitors: promise or peril?
por: Mengle-Gaw, Laurel J, et al.
Publicado: (2002)

Cyclooxygenase (COX) Inhibitors and the Newborn Kidney
por: Smith, Francine G., et al.
Publicado: (2012)

Colorectal Carcinoma, Cyclooxygenases, and COX Inhibitors
por: Ganduri, Vinutna, et al.
Publicado: (2022)

Chemotherapy-induced neutropenia and treatment efficacy in advanced non-small-cell lung cancer: a pooled analysis of 6 randomized trials
por: Gargiulo, Piera, et al.
Publicado: (2021)

Dual Effects of Cyclooxygenase Inhibitors in Combination With CD19.CAR-T Cell Immunotherapy
por: Yang, Mingya, et al.
Publicado: (2021)

Cemiplimab combined with chemotherapy versus chemotherapy in advanced non-small cell lung cancer: an updated EMPOWER-Lung 3 trial-based cost-effectiveness analysis
por: Zhu, Gaofeng, et al.
Publicado: (2023)

Antiangiogenic Agents in Combination with Chemotherapy in Patients with Advanced Non-Small Cell Lung Cancer
por: Ulahannan, Susanna V, et al.
Publicado: (2011)

Cyclooxygenase-2 expression is a prognostic biomarker for non-small cell lung cancer patients treated with adjuvant platinum-based chemotherapy
por: Shimizu, Katsuhiko, et al.
Publicado: (2015)

Neoadjuvant immunotherapy combined with chemotherapy for local advanced non-small cell lung cancer: a case report
por: Yang, Jie, et al.
Publicado: (2021)

Survival benefit with checkpoint inhibitors versus chemotherapy is modified by brain metastases in patients with recurrent small cell lung cancer
por: Althoff, Friederike C., et al.
Publicado: (2023)

Comparison of the benefits of celecoxib combined with anticancer therapy in advanced non-small cell lung cancer: A meta-analysis
por: Zhang, Wei, et al.
Publicado: (2020)

Monitoring Blood Immune Cells in Patients with Advanced Small Cell Lung Cancer Undergoing a Combined Immune Checkpoint Inhibitor/Chemotherapy
por: Riemann, Dagmar, et al.
Publicado: (2023)

Angiogenesis inhibitors rechallenge in patients with advanced non-small-cell lung cancer: a pooled analysis of randomized controlled trials
por: Zhao, Lingdi, et al.
Publicado: (2015)

Comparison of benefit–risk preferences of patients and physicians regarding cyclooxygenase-2 inhibitors using discrete choice experiments
por: Byun, Ji-Hye, et al.
Publicado: (2016)

Rechallenge pemetrexed-based chemotherapy provides an option for initially benefited patients with advanced lung adenocarcinoma
por: Wang, Jia-Ni, et al.
Publicado: (2021)

Triplet chemotherapy combination with cisplatin, gemcitabine and docetaxel in patients with chemotherapy-naive advanced non-small cell lung cancer
por: TAS, FARUK, et al.
Publicado: (2013)

Inhibition of cyclooxygenase-2 sensitizes lung cancer cells to radiation-induced apoptosis
por: Han, Zhi-Qiang, et al.
Publicado: (2017)

Inhibition of cyclooxygenase-2 sensitizes lung cancer cells to radiation-induced apoptosis
por: Han, Zhi-Qiang, et al.
Publicado: (2019)

Effects of combining Taxol and cyclooxygenase inhibitors on the angiogenesis and apoptosis in human ovarian cancer xenografts
por: LI, WEI, et al.
Publicado: (2013)

Antimetastatic activity of a cyclooxygenase-2 inhibitor
por: Roche-Nagle, G, et al.
Publicado: (2004)

Risk of Cardiovascular Events and Cyclooxygenase-2 Inhibitors
por: Tabrizchi, Reza
Publicado: (2006)

Celecoxib: a selective cyclooxygenase-2 inhibitor
por: Gandelman, M
Publicado: (2003)

Effects of Cyclooxygenase Inhibitors on Apoptotic Neuroretinal Cells
por: Brust, Anja-Kristina, et al.
Publicado: (2008)

Renal Effects of Prostaglandins and Cyclooxygenase-2 Inhibitors
por: Kim, Gheun-Ho
Publicado: (2008)

Antiproliferative Benzoindazolequinones as Potential Cyclooxygenase-2 Inhibitors
por: Molinari, Aurora, et al.
Publicado: (2019)

Can neoadjuvant chemoradiotherapy combined with immunotherapy benefit patients with microsatellite stable locally advanced rectal cancer? a pooled and integration analysis
por: Yue, Yumin, et al.
Publicado: (2023)

Topoisomerase II alpha expression and the benefit of adjuvant chemotherapy for postoperative patients with non-small cell lung cancer
por: Yan, Shi, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_n5rihthm0r4b1t9egv2kn2obdi